Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
Kazue Yoneda, Taiji Kuwata, Masatoshi Kanayama, et al.
British Journal of Cancer (2019) Vol. 121, Iss. 6, pp. 490-496
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene
Shuiping Liu, Qiujie Li, Guohua Li, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 11
Open Access | Times Cited: 138
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Mohammad Kazemi, Maryam Sadri, Alireza Najafi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 81
Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis
Hina Qayoom, Shazia Sofi, Manzoor Ahmad Mir
Immunologic Research (2023) Vol. 71, Iss. 4, pp. 588-599
Closed Access | Times Cited: 40
Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully
Baisheng Lin, Likun Du, Hongmei Li, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 132, pp. 110873-110873
Open Access | Times Cited: 128
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Mengke Niu, Ming Yi, Ning Li, et al.
Experimental Hematology and Oncology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 85
Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges
Shuqin Xing, Kaiwen Hu, Yafei Wang
Aging and Disease (2022) Vol. 13, Iss. 6, pp. 1615-1615
Open Access | Times Cited: 45
Ionizing Radiation Triggers the Antitumor Immunity by Inducing Gasdermin E-Mediated Pyroptosis in Tumor Cells
Wei Cao, Guodong Chen, Lijun Wu, et al.
International Journal of Radiation Oncology*Biology*Physics (2022) Vol. 115, Iss. 2, pp. 440-452
Closed Access | Times Cited: 38
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
François Ghiringhelli, Frédéric Bibeau, Laurent Greillier, et al.
EBioMedicine (2023) Vol. 92, pp. 104633-104633
Open Access | Times Cited: 34
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Xin Zhang, Xuemei Wang, Lijian Hou, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
Leilei Wu, Zhenshan Zhang, Menglin Bai, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 15
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”
Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, et al.
Cancer Treatment Reviews (2025), pp. 102918-102918
Open Access
Computerized tumor-infiltrating lymphocytes density score predicts survival of patients with resectable lung adenocarcinoma
Xipeng Pan, Huan Lin, Chu Han, et al.
iScience (2022) Vol. 25, Iss. 12, pp. 105605-105605
Open Access | Times Cited: 25
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Joao V. Alessi, Biagio Ricciuti, Xinan Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers
Wei Zhang, Junping Shi, Yingying Wang, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 4, pp. 1001-1014
Closed Access | Times Cited: 36
The role of radiotherapy in the age of immunotherapy
Hiro Sato, Sandra Demaria, Tatsuya Ohno
Japanese Journal of Clinical Oncology (2020) Vol. 51, Iss. 4, pp. 513-522
Open Access | Times Cited: 34
The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer
Philipp Zens, Corina Bello, Amina Scherz, et al.
Modern Pathology (2022) Vol. 35, Iss. 12, pp. 1848-1859
Open Access | Times Cited: 20
A Three‐in‐One Nanoscale Coordination Polymer for Potent Chemo‐Immunotherapy
Jing Liu, Xiaomin Jiang, Xuanyu Feng, et al.
Small Methods (2023) Vol. 7, Iss. 5
Open Access | Times Cited: 11
Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
Lin Ma, Liufu Deng, Jianfeng Peng, et al.
Cancer Biology and Medicine (2024) Vol. 20, Iss. 12, pp. 1035-1046
Open Access | Times Cited: 3
Tumor microenvironment, immune response and post-radiotherapy tumor clearance
Michael I. Koukourakis, Alexandra Giatromanolaki
Clinical & Translational Oncology (2020) Vol. 22, Iss. 12, pp. 2196-2205
Closed Access | Times Cited: 31
Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
Chia‐Hsun Chu, Tzu‐Hsuan Chiu, Chin‐Chou Wang, et al.
Thoracic Cancer (2020) Vol. 11, Iss. 6, pp. 1541-1549
Open Access | Times Cited: 30
DNA Repair and Signaling in Immune-Related Cancer Therapy
Sangeeta Kakoti, Hiro Sato, Siddhartha Laskar, et al.
Frontiers in Molecular Biosciences (2020) Vol. 7
Open Access | Times Cited: 30
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
Meng Lu, Jianfang Xu, Ying Ye, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 23
Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
Noriko Kishi, Yukinori Matsuo, Takashi Shintani, et al.
Journal of Radiation Research (2022) Vol. 64, Iss. 1, pp. 142-153
Open Access | Times Cited: 17
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study
Fiona Hegi‐Johnson, Stacey E. Rudd, Christian Wichmann, et al.
International Journal of Radiation Oncology*Biology*Physics (2023) Vol. 117, Iss. 3, pp. 675-682
Closed Access | Times Cited: 9
Analysis of radiotherapy‑induced alteration of CD8+ T cells and PD‑L1 expression in patients with uterine cervical squamous cell carcinoma
Yasumasa Mori, Hiro Sato, Takuya Kumazawa, et al.
Oncology Letters (2021) Vol. 21, Iss. 6
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top